MPLT on Nasdaq

MapLight Therapeutics, Inc.

American pharmaceutical preparations company based in Redwood City. Summary from the record

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with another stock.

  • TickerMPLT on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersRedwood City, California1
  • Incorporated inDE2
  • Business address800 Chesapeake Drive, Redwood City, Ca 940632
  • Filer categoryNon-accelerated filer, Smaller reporting company, Emerging growth company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income3-$169.1M in 2025+104% since 2024
-$200.0M-$150.0M-$100.0M-$50.0M02024: -$82.9M-$82.9M20242025: -$169.1M-$169.1M2025+104%
Net income3-$161.2M in 2025+108% since 2024
-$200.0M-$150.0M-$100.0M-$50.0M02024: -$77.6M-$77.6M20242025: -$161.2M-$161.2M2025+108%

Every line of the income statement as filed: the last 2 fiscal years, latest first.3

Period ending2025-12-312024-12-31
Research and development$138.3M$68.5M
General and administrative$30.7M$14.4M
Total operating expenses$169.1M$82.9M
Loss from operations-$169.1M-$82.9M
Interest income$5.5M$4.5M
Loss from equity method investment-$986.0K
Other income, net$2.4M$1.8M
Total other income, net$7.9M$5.4M
Net loss-$161.2M-$77.6M
Net loss per share - basic-$18.56-$105.38
Net loss per share - diluted-$18.56-$105.38
Weighted-average number of common shares outstanding - basic8.7M shares736.2K shares
Weighted-average number of common shares outstanding - diluted8.7M shares736.2K shares
Unrealized (loss) gain on available-for-sale investments-$391.0K$163.0K
Comprehensive loss-$161.5M-$77.4M

Compare MapLight Therapeutics, Inc. with another company

Leadership

Who has led MapLight Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Christopher A. Kroeger2025–now

Chief financial officer

  1. Vishwas Setia2025–now
Board members and other officers (14)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive OfficerJonathan A Gillis named Nov 10, 2022 to Jul 28, 202522
  • Executive OfficerCharmaine A Lykins named Nov 3, 202323
  • DirectorPeter A Bisgaard named Nov 10, 2022 to Jul 28, 202522

Former names

  • Alvarado Therapeutics, Inc.Mar 8, 2019 to Mar 22, 20192

Timeline

  1. Oct 27, 2025New chief executive Christopher A. Kroeger becomes CEO7

Filings

199 filings to the SEC since October 2021: 1 annual reports, 3 quarterly reports, 11 major events, 94 insider forms, 9 large holders, 4 private raises, 77 other. The latest 20:

  1. Oct 15, 2026144 EDGAR
  2. Oct 15, 2026144 EDGAR
  3. Oct 15, 2026144 EDGAR
  4. Oct 15, 2026144 EDGAR
  5. Oct 15, 2026144 EDGAR
  6. Oct 15, 2026144 EDGAR
  7. Oct 15, 2026144 EDGAR
  8. Sep 23, 2026EFFECT EDGAR
  9. Sep 23, 2026424B3 EDGAR
  10. Sep 18, 20264 EDGAR
  11. Sep 18, 2026S-1/A EDGAR
  12. Sep 16, 2026144 EDGAR
  13. Sep 9, 2026S-1 EDGAR
  14. Aug 20, 2026SCHEDULE 13G EDGAR
  15. Aug 19, 20264 EDGAR
  16. Aug 19, 20264 EDGAR
  17. Aug 19, 20264 EDGAR
  18. Aug 19, 20264 EDGAR
  19. Aug 19, 20264 EDGAR
  20. Aug 19, 20264 EDGAR

The 199 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

78 open-market trades by officers, directors and large owners since October 2021: 11 buys and 67 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 16, 2026Hanson KristopherGeneral CounselSale16,509$11.67$192.7KForm 4
Aug 14, 2026Catalyst4, Inc.10% ownerBuy4,400,000$11.38$50.1MForm 4
Aug 3, 2026Lillie James WoodruffChief Scientific OfficerSale22,082$12.54$276.9KForm 4
Jul 30, 2026Catalyst4, Inc.10% ownerBuy1,000,000$13.00$13.0MForm 4
Jul 29, 2026Catalyst4, Inc.10% ownerBuy3,000$12.63$37.9KForm 4
Jul 28, 2026Catalyst4, Inc.10% ownerBuy206,225$11.04$2.3MForm 4
Jul 28, 2026Cox TroyDirectorBuy15,620$9.52$148.7KForm 4
Jul 17, 2026Kreitzer AnatolChief Discovery OfficerSale17,173$37.60$645.7KForm 4
Jul 17, 2026Foff Erin PennockChief Medical OfficerSale3,656$37.90$138.6KForm 4
Jul 17, 2026Hanson KristopherGeneral CounselSale1,130$37.90$42.8KForm 4
Jul 17, 2026Lillie James WoodruffChief Scientific OfficerSale2,077$37.90$78.7KForm 4
Jul 17, 2026GILLIS JONATHANCAO and Interim CFOSale18,469$37.60$694.5KForm 4
Jul 17, 2026Kroeger Christopher A.Chief Executive OfficerSale16,779$37.90$635.9KForm 4
Jul 16, 2026Kreitzer AnatolChief Discovery OfficerSale9,056$36.80$333.2KForm 4
Jul 16, 2026Foff Erin PennockChief Medical OfficerSale15,047$36.77$553.3KForm 4
Jul 16, 2026Hanson KristopherGeneral CounselSale8,118$36.78$298.6KForm 4
Jul 16, 2026Lillie James WoodruffChief Scientific OfficerSale8,547$36.79$314.4KForm 4
Jul 16, 2026GILLIS JONATHANCAO and Interim CFOSale8,455$36.80$311.1KForm 4
Jul 16, 2026Kroeger Christopher A.Chief Executive OfficerSale69,082$36.79$2.5MForm 4
Jul 15, 2026Kreitzer AnatolChief Discovery OfficerSale10,055$36.49$366.9KForm 4

All 78 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Jul 18, 2025Raised $188.2 million in a private offering of equity Form D: $372.4 million offered in all Form D
  2. Jul 5, 2023Raised $105 million in a private offering of equity Form D: $225 million offered in all Form D
  3. Oct 25, 2022Raised $12 million in a private offering of equity Form D: 1 investor so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Novo Holdings A/s3,686,622$132.1M7.7%No change
Fcpm III Services B.v.3,226,400$115.6M15.4%No change
Goldman Sachs Group Inc1,948,312$69.8M0.0%−46,561
BlackRock, Inc.1,025,134$36.7M0.0%−314,597
Nan Fung Group Holdings Ltd971,253$34.8M26.5%No change
5AM Venture Management, LLC950,011$34.0M11.8%No change
Sanofi912,041$32.7M6.1%No change
State Street Corp852,150$30.5M0.0%+513,034
Fmr LLC823,556$29.5M0.0%+619,055
Vanguard Capital Management LLC784,150$28.1M0.0%+64,330
Blue Owl Capital Holdings LP729,929$26.2M4.0%−276,000
Paradigm Biocapital Advisors LP685,852$24.6M0.5%New
Pivotal bioVenture Partners Investment Advisor LLC611,446$21.9M7.1%−1
Velan Capital Investment Management LP492,893$17.7M10.8%No change
Siren, L.L.C.450,000$16.1M0.3%No change
Capital World Investors415,730$14.9M0.0%New
Geode Capital Management, LLC402,051$14.4M0.0%−79,150
Baker Bros. Advisors LP364,705$13.1M0.1%No change
DAFNA Capital Management LLC171,006$6.1M1.2%No change
BNP PARIBAS ASSET MANAGEMENT Holding S.A.170,862$6.1M0.0%−96,884
Freestone Grove Partners LP168,912$6.1M0.0%−145,045
Charles Schwab Investment Management Inc136,818$4.9M0.0%−24,328
Millennium Management LLC128,841$4.6M0.0%New
Superstring Capital Management LP125,432$4.5M2.8%−66,707
Vanguard Fiduciary Trust Co123,135$4.4M0.0%−8,096

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28